title: Re: Boyer et al.: Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials (Ophthalmology 2015;122:2504-13).
authors.affiliation: Dr. Rajendra Prasad Centre for Ophthalmic Sciences, AIIMS, New Delhi, India.
authors.forename: Brijesh
authors.initials: B
authors.lastname: Takkar
authors.affiliation: Dr. Rajendra Prasad Centre for Ophthalmic Sciences, AIIMS, New Delhi, India. Electronic address: shoryaazad@hotmail.com.
authors.forename: Shorya
authors.initials: S
authors.lastname: Azad
mesh_terms: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D008269:Macular Edema; D000069579:Ranibizumab; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab